Two medicines, side by side
Ketoprofen vs warfarin
Ketoprofen is labeled for osteoarthritis, rheumatoid arthritis and pain; warfarin for blood clots (dvt and pe) and atrial fibrillation. Their labels share no use, so they are not alternatives to each other. Drugs@FDA records approvals of ketoprofen since 1986 and of warfarin since 1954. Pharmacies paid $6.46 per ketoprofen ER 200 mg capsule and $0.093 per warfarin sodium 2 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, ketoprofen is a nonsteroidal anti-inflammatory drug and warfarin a vitamin k antagonist.
Check it at the source: the ketoprofen FDA label on DailyMed (effective February 15, 2026); the warfarin FDA label on DailyMed (effective May 29, 2026).
Highlights of the ketoprofen record
Ketoprofen (Orudis) · label of February 15, 2026
Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Ketoprofen capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Used for
From the label: indicationsCarefully consider the potential benefits and risks of ketoprofen capsules USP and other treatment options before deciding to use ketoprofen capsules USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. Ketoprofen capsules USP are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. […]
On the market
- Earliest approval on file
- January 9, 1986
- Generic labelers
- 5 labelers
- Pharmacy cost
- $6.46 per capsule
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the warfarin record
Warfarin (Coumadin) · label of May 29, 2026
BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [see Warnings and Precautions (5.1) ]. Perform regular monitoring of INR in all treated patients [see Dosage and Administration (2.1) ]. Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy [see Drug Interactions (7) ]. Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [see Patient Counseling Information (17) ].
Used for
From the label: indicationsWarfarin sodium tablets are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement. […]
On the market
- Earliest approval on file
- June 8, 1954
- Generic labelers
- 19 labelers
- Pharmacy cost
- $0.093 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 7
Source: FDA drug labels via openFDA (Ketoprofen label of February 15, 2026, Warfarin label of May 29, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do ketoprofen and warfarin differ on the record?
In FDA's classes, ketoprofen is a nonsteroidal anti-inflammatory drug and warfarin a vitamin k antagonist.
Both labels carry a boxed warning; the records quote them.
Generics: ketoprofen since 1992; warfarin since 1997 (Drugs@FDA).
| Ketoprofen | Warfarin | |
|---|---|---|
| Labeled for | Osteoarthritis, Rheumatoid arthritis, Pain | Blood clots (DVT and PE), Atrial fibrillation |
| Pharmacologic class | Nonsteroidal Anti-inflammatory Drug | Vitamin K Antagonist |
| How it works (label) | n/a | Warfarin acts by inhibiting the synthesis of vitamin K-dependent clotting factors, which include Factors II, VII, IX, and X, and the anticoagulant proteins C and S. |
| Half-life (label) | n/a | Excretion The terminal half-life of warfarin after a single dose is approximately 1 week; however, the effective half-life ranges from 20 to 60 hours, with a mean of about 40 hours. |
| Earliest approval on file (Drugs@FDA) | January 9, 1986 | June 8, 1954 |
| First generic approved | December 22, 1992 | March 26, 1997 |
| Generic labelers (NDC) | 5 labelers | 19 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $6.46 per capsule (Ketoprofen ER 200 mg capsule) | $0.093 per tablet (Warfarin sodium 2 mg tablet) |
| 12-month price change | +14% | +2% |
| Boxed warning | Yes | Yes |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 0 | 7 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 13,039 | 127,492 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
Do their labels mention each other?
Ketoprofen label, drug interactionsWarfarin The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.
Warfarin label, drug interactionsDrug Class: Nonsteroidal Anti-Inflammatory Agents; Specific Drugs: celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac
Source: FDA drug labels via openFDA
What do the labels say about using others of their kind?
Ketoprofen label, drug interactionsThe clinical significance of these changes is not known; however, as with other NSAIDs, concomitant administration of ketoprofen and aspirin is not generally recommended because of the potential of increased adverse effects.
Source: FDA drug labels via openFDA
What next?
- Alternatives to ketoprofen
- every medicine labeled for the same conditions